RIGI and neoplasm: In the present study, we achieved effective immunomodulation of the tumour microenvironment and potent anti‐tumour activity using RBCEVs as delivery vehicles for RIG‐I agonists without any observable adverse effects, suggesting the advantages of RBCEVs for clinical application.